Loading…
Reported covered position: Legislative Assistant to Senator Joni Ernst; Legislative Assistant, Legislative Aide & Legislative Correspondent to Senator Mike Johanns; Staff Assistant to Senator Judd Gregg; Staff Assistant to Senator John E. Sununu
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Sickle Cell Disease Comprehensive Care Act
Client: TERUMO BCT, INC. · Firm: TERUMO BCT, INC.
-Access to Therapeutic Apheresis, generally. -Sickle Cell Disease issues, generally; S.1852, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023. -Blood collection issues, generally. -Medical device sterilization. -ARPA-H, cell collections issues, generally. -H.R.7432, The Sickle Cell Disease Comprehensive Care Act.
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023
Client: TERUMO BCT, INC. · Firm: TERUMO BCT, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
TERUMO BCT, INC. via TERUMO BCT, INC.
2024 · second_quarter · 2T
-Access to Therapeutic Apheresis, generally. -Issues related to CY 2024 Physician Fee Schedule. -Issues related to CY 2024 OPPS Proposed Rule. -Sickle Cell Disease issues, generally.
-Access to Therapeutic Apheresis, generally. -Sickle Cell Disease issues, generally; S.1852, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023. -Blood collection issues, generally. -Medical device sterilization. -ARPA-H, cell collections issues, generally. -H.R.7432, The Sickle Cell Disease Comprehensive Care Act.
Source: Senate LDA
-Access to Therapeutic Apheresis, generally. -Sickle Cell Disease issues, generally; S.1852, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023. -Blood collection issues, generally. -Medical device sterilization. -ARPA-H, cell collections issues, generally.
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023
Client: TERUMO BCT, INC. · Firm: TERUMO BCT, INC.
-Access to Therapeutic Apheresis, generally. -Sickle Cell Disease issues, generally; S.1852, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023. -Blood collection issues, generally. -Medical device sterilization. -ARPA-H, cell collections issues, generally. -H.R.7432, The Sickle Cell Disease Comprehensive Care Act.
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023
Client: TERUMO BCT, INC. · Firm: TERUMO BCT, INC.
-Access to Therapeutic Apheresis, generally. -Sickle Cell Disease issues, generally; S.1852, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023. -Blood collection issues, generally. -Medical device sterilization.
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023
Client: TERUMO BCT, INC. · Firm: TERUMO BCT, INC.
-Access to Therapeutic Apheresis, generally. -Sickle Cell Disease issues, generally; S.1852, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023. -Blood collection issues, generally. -Medical device sterilization.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
TERUMO BCT, INC. via TERUMO BCT, INC.
2024 · first_quarter · Q1
-Export license applications.
-Access to Therapeutic Apheresis, generally. -Issues related to CY 2024 Physician Fee Schedule. -Issues related to CY 2024 OPPS Proposed Rule. -Sickle Cell Disease issues, generally.
-Access to Therapeutic Apheresis, generally. -Sickle Cell Disease issues, generally; S.1852, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023. -Blood collection issues, generally. -Medical device sterilization. -ARPA-H, cell collections issues, generally.
Filing targets: Bureau of Industry and Security (BIS), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
TERUMO BCT, INC. via TERUMO BCT, INC.
2023 · fourth_quarter · Q4
-Access to Therapeutic Apheresis, generally. -Sickle Cell Disease issues, generally; S.1852, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023. -Blood collection issues, generally. -Medical device sterilization.
-Access to Therapeutic Apheresis, generally. -Issues related to CY 2024 Physician Fee Schedule. -Issues related to CY 2024 OPPS Proposed Rule. -Sickle Cell Disease issues, generally.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
TERUMO BCT, INC. via TERUMO BCT, INC.
2023 · third_quarter · Q3
-Access to Therapeutic Apheresis, generally. -Issues related to CY 2024 Physician Fee Schedule. -Issues related to CY 2024 OPPS Proposed Rule. -Sickle Cell Disease issues, generally.
-Access to Therapeutic Apheresis, generally. -Sickle Cell Disease issues, generally; S.1852, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023. -Blood collection issues, generally. -Medical device sterilization.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TERUMO BCT, INC. via TERUMO BCT, INC.
2023 · second_quarter · RR
medical device manufacturing health care technology health care access
medical device manufacturing health care technology health care access
medical device manufacturing health care technology health care access
medical device manufacturing health care technology health care access